Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

BACKGROUND: An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and complex therapy. It requests substantial upfront inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139174/
https://www.ncbi.nlm.nih.gov/pubmed/30219040
http://dx.doi.org/10.1186/s12885-018-4788-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139174/
https://www.ncbi.nlm.nih.gov/pubmed/30219040
http://dx.doi.org/10.1186/s12885-018-4788-5

Ejemplares similares